Table 1.
Ongoing trials involving polatuzumab vedotin-piiq in DLBCL
| Drug(s) | Clinical phase | Indications/endpoints | Status | Identifiers |
|---|---|---|---|---|
| Polatuzumab vedotin + DA-EPCH-R | I | Previously untreated aggressive large B-cell lymphoma; safety and toxicity | Not yet recruiting | NCT04231877 |
| Polatuzumab vedotin + R-CHP | III | Previously untreated diffuse large B-cell lymphoma; PFS | Recruiting | NCT03274492 |
| Polatuzumab vedotin + Mosunetuzumab | Ib/II | R/R FL or DLBCL; Safety and efficacy DLT MTD | Recruiting | NCT03671018 |
| Polatuzumab vedotin + BR | III | Transplant ineligible R/R DLBCL; Complete remission rate | Not yet recruiting | NCT04236141 |
| Polatuzumab vedotin with R-GemOx | III | R/R DLBCL; Safety and OS | Recruiting | NCT04182204 |
| Polatuzumab vedotin + Venetoclax with Rituximab or Obinituzumab | Ib/II | R/R FL or R/R DLBCL; Complete remission rate and safety | Active, not recruiting | NCT02611323 |
| Polatuzumab vedotin + Lenalidomide with Rituximab or Obinituzumab | Ib/II | R/R FL or R/R DLBCL; Complete remission rate and safety | Active, not recruiting | NCT02600897 |
| Polatuzumab vedotin + Glofitamab | Ib | R/R non-Hodgkin B-cell lymphoma; DLTs | Recruiting | NCT03533283 |
| Polatuzumab vedotin + R mini-CHP | III | Previously untreated DLBCL; PFS | Not yet recruiting | NCT04332822 |
| Polatuzumab vedotin + Bendamustine with Rituximab or Obinituxumab | Ib/II | R/R FL or DLBCL; safety and tolerability, CR rate | Active, not recruiting | NCT02257567 |
| Polatizumab vedotin + CHP and Mosunetuzumab | Ib/II | R/R non-Hodgkin B-cell lymphoma; Safety and complete response rate | Recruiting | NCT03677141 |
BR, bendamustine rituximab; DA-EPCH-R, dose-adjusted-etoposide, prednisone, vincristine (Oncovin), cyclophosphamide, doxorubicin-rituximab; DLBCL, diffuse large B-cell lymphoma; DLT, dose-limiting toxicities; FL, follicular lymphoma; MTD, maximum tolerated dose; OS, overall survival; PFS, progression free survival; R-CHP, rituximab-cyclophosphamide, doxorubicin, prednisone; R-GemOx, rituximab, gemcitabine, oxaliplatin.